Abraxis BioScience, Inc. (Public, NASDAQ:ABBI)
Abraxis BioScience Launches New Abraxane Patient Assistance Program
Comprehensive Program Provides Access to Care for Cancer Patients
Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global
biopharmaceutical company today announced the la
Trinity Biotech plc (ADR) (Public, NASDAQ:TRIB)
Trinity Biotech Announces Quarter 3 Results Revenues Increase 25%
and EBITDA Exceeds US$5 Million
October 26, 2006 -- Trinity Biotech plc (NASDAQ: TRIB) (DUBLIN:
TRIB.I), a leading developer and manufacturer of diagnostic products
for the point
Allergan, Inc. (Public, NYSE:AGN)
Allergan profit falls in 3Q, plans to buy French company
Los Angeles Business from bizjournals - November 1, 2006
Print this Article Email this Article Reprints RSS Feeds Most Viewed
Most Emailed
Allergan Inc.'s third quarter profit was down because of charges
Celgene Corporation (Public, NASDAQ:CELG)
Gilead Sciences Completes Acquisition of Raylo Chemicals Inc. and
Celgene Announces Pricing of Common Stock Offering
Biotechnology industry news Gilead Sciences, Inc. (Nasdaq:GILD)
recently announced that the company has completed its acquisition of
MedImmune, Inc. (Public, NASDAQ:MEDI)
MedImmune to Present at the CIBC World Markets 17th Annual Healthcare
Conference and ViroPharma to Present at the Cowen and Company Annual
Global Healthcare Conference
http://tech.groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://
Teva Pharmaceutical Industries Ltd (ADR) (Public, NASDAQ:TEVA)
Mundipharma Receives Boost to European Oxycontin Patent Position;
Teva Withdraws Challenge from European Patent Office
Mundipharma International Ltd announces a strengthening of its
position with respect to European patents on
Vertex Pharmaceuticals Incorporated (Public, NASDAQ:VRTX)
Vertex presents mixed results in hepatitis C drug
30th October 2006
By Victoria Harrison
Vertex has presented mixed results from its phase Ib trial of its
hepatitis C drug, saying that some patients still had the virus when
combined wit
Biogen Idec Inc. (Public, NASDAQ:BIIB)
In earnings news, Biogen Idec (NASDAQ:BIIB) announced third-quarter
net profit of $156.6 million, or 45 cents per share, from $27.2
million, or eight cents per share, in the prior year. Excluding items,
earnings surged 67 percent to 60 cents per share, o
Cardinal Health, Inc. (Public, NYSE:CAH)
DuPont reaches settlement with Cardinal Health
Business First of Columbus - October 30, 2006
Print this Article Email this Article Reprints RSS Feeds Most Viewed
Most Emailed
Chemicals giant E.I. DuPont De Nemours & Co. said Monday it has
reached a sett
Millennium Pharmaceuticals, Inc. (Public, NASDAQ:MLNM)
CIBC World Markets 17th Annual Healthcare Conference to Webcast
Millennium Presentation
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company
based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for
Injection, a nov
Hospira, Inc. (Public, NYSE:HSP)
George Soros sold out his holdings in Pharmaceuticals operator
Hospira Inc.(HSP) during the 3-months ended 2006-06-30. His sale
prices were between $ 36.95
Press Release Source: Hospira, Inc.
Hospira Expands Board of Directors
Tuesday October 31, 11:00
Amgen, Inc. (Public, NASDAQ:AMGN)
Amgen, Inc. AMGN Amgen Foundation Launches $25 Million Amgen Scolars
Program.
Amgen Foundation Launches $25 Million Undergraduate Research Program
Amgen Scholars Will Provide Hands-on Science Research Experience at
10 of the Nation's Premier Universities
THO
Forest Laboratories, Inc. (Public, NYSE:FRX)
Forest Laboratories recruitment to resume in stroke trial
Forest Laboratories Inc. (FRX) plans to resume patient enrollment in
its DIAS-2 Phase IIb/III desmoteplase study after an independent data
monitoring committee reviewed data concerning a poten
Genentech, Inc. DNA
Genentech Repeats as 'Fastest Company in Silicon Valley' in 2006
Comerica Corporate Challenge at Metro Silicon Valley Marathon
SAN JOSE, Calif., Nov. 3 -- Top performing companies in Silicon
Valley each year are recognized as among the "Fastest Growing." Now,
for the s
Serono S.A. (ADR) (Public, NYSE:SRA)
Germany's Merck gets US antitrust nod for Serono
WASHINGTON, Oct 31 (Reuters) - U.S. antitrust authorities have
approved German drugmaker Merck KGaA's (MRCG.DE: Quote, Profile,
Research) takeover of biotech firm Serono SA (SEO.VX: Quote,
Profile, Researc
Invitrogen Corporation (Public, NASDAQ:IVGN)
Stratagene Ordered to Shell Out Triple the Amount Previously Awarded
in the Invitrogen Lawsuit
In a patent infringement case, a U.S. court awarded Invitrogen $16.2
million in damages.
On July 25, 2006, the jury found that Stratagene had willfully
Genzyme Corporation (Public, NASDAQ:GENZ)
Genzyme sells new gene test for cystic fibrosis
The biotechnology company said the diagnostic test can detect about
98 percent of about 1,200 disease-causing variations in a gene, in
which mutations are linked to cystic fibrosis.
BioMarin Announces
Gilead Sciences, Inc. (Public, NASDAQ:GILD)
Gilead Sciences Extends Expiration Date for Tender Offer for Myogen
Until November 13, 2006
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:
GILD) today announced that it has extended the initial expiration
date for its previousl
18 matches
Mail list logo
